PPARA and Hepatic fibrosis: Lanifibranor is a pan-PPAR agonist targeting α, β/γ, and δ, which can improve macrophage activation to reduce liver fibrosis and inflammation in preclinical models, and its efficacy is stronger than that of single or dual PPAR agonists (Sven et al., 2020).